Listing 5.12 Pancreas Transplantation in 2026: The Automatic 12 Month SSDI Approval from Transplant Date for Simultaneous Pancreas-Kidney (SPK), Pancreas After Kidney (PAK), and Pancreas Transplant Alone (PTA), How Recurrent Autoimmune Diabetes and Rejection Episodes Extend the Disability Period, and How Pre-Transplant Type 1 Diabetes with End-Organ Damage Establishes an Earlier Onset Date

By Anthony Albert, Benefits Research Director. Published July 25, 2026.

Pancreas transplantation is unusual in the SSA Blue Book. It has its own listing (5.12) in the digestive system section, even though the pancreas is not really a digestive organ in the way the intestine or liver is. What matters is that if you got a pancreas transplant, you get 1 year of automatic disability from the surgery date. That is the rule, and it applies regardless of whether the transplant was simultaneous with a kidney (SPK), after a kidney (PAK), or alone (PTA).

Pancreas transplant is almost always done for Type 1 diabetes. It is not typically used for Type 2 diabetes. The point of the transplant is to eliminate the need for insulin and to stop or slow progression of diabetic complications. Most recipients had Type 1 diabetes for 20 to 30 years before transplant, and most had significant end-organ damage: diabetic nephropathy progressing to end-stage renal disease, retinopathy, neuropathy, cardiovascular disease.

That is why the pre-transplant disability picture is usually already established. A Type 1 diabetic on dialysis awaiting a pancreas transplant likely qualified for SSDI years earlier under Listing 6.03 (CKD requiring dialysis) or 6.05 (CKD with impaired kidney function).

This article covers the exact 5.12 text, how the 12 month window works, the three transplant modalities and why they matter for the CDR, what happens at the CDR, common complications that extend disability past 12 months, pediatric 105.12, and how pre-transplant Type 1 diabetes with end-organ damage establishes an earlier onset date. Four worked cases at the end.

The Listing 5.12 Text

Section 5.00G groups 5.09 (liver), 5.11 (small intestine), and 5.12 (pancreas) transplantation together. If you receive any of these transplants, SSA considers you disabled under the listing for 1 year from the transplant date. After that, SSA evaluates residual impairment based on:

• Adequacy of post-transplant function (both pancreas graft and any accompanying kidney graft)
• Requirement for post-transplant antiviral therapy (usually CMV prophylaxis for 3 to 6 months)
• Frequency and severity of rejection episodes
• Comorbid complications (infections, PTLD, graft thrombosis, ongoing diabetic complications)
• All adverse treatment effects

SSA notes that people who receive digestive organ transplants generally have impairments that meet the disability definition before transplantation. The 1 year clock does not restrict onset. Onset is determined based on the facts of the case, typically anchored by pre-transplant diabetes with end-organ damage.

The Three Pancreas Transplant Modalities

Pancreas transplant is done in three distinct clinical scenarios. Each has different pre-transplant qualification paths, different post-transplant complication profiles, and different CDR considerations.

SPK: Simultaneous Pancreas-Kidney

About 75 percent of pancreas transplants. Kidney and pancreas transplanted at the same operation, usually from the same deceased donor. Indication is Type 1 diabetes with end-stage renal disease. Most recipients have been on dialysis or approaching dialysis. Under 5.12 rules, the pancreas component gives 1 year auto disability, and the kidney component gives 1 year auto disability under 6.04. Either listing applies. Outcomes are the best of the three modalities: 1 year pancreas graft survival is 87 to 92 percent, 1 year kidney graft survival is 94 to 96 percent per UNOS 2024 data.

PAK: Pancreas After Kidney

About 15 percent of pancreas transplants. Kidney transplanted first (often a living donor), then pancreas transplanted later as a separate operation months or years later. Indication is Type 1 diabetes with prior kidney transplant, ongoing insulin dependency. Under 5.12, the pancreas transplant date starts the 1 year clock. The prior kidney transplant date started its own 6.04 1 year clock and may already be past. Pancreas graft survival at 1 year is 82 to 87 percent, lower than SPK due to the isolated pancreas immune response.

PTA: Pancreas Transplant Alone

About 10 percent of pancreas transplants. Only pancreas transplanted. Indication is Type 1 diabetes with hypoglycemic unawareness or brittle diabetes despite optimal medical management, without significant kidney disease. Typically the recipient has near-normal kidney function (eGFR 60 or higher). Under 5.12, 1 year auto from transplant date. Pancreas graft survival at 1 year is 78 to 83 percent, the lowest of the three modalities. Higher rejection rate because the pancreas is alone and there is no kidney to co-monitor for rejection.

Indications for Pancreas Transplant

Type 1 diabetes with end-stage renal disease (SPK indication)

Most common. Requires diabetic nephropathy progressing to CKD stage 5 (eGFR under 20 or on dialysis) with historical documentation of Type 1 diabetes (C-peptide low, GAD antibodies or IA-2 antibodies positive typically). Referral criteria: eGFR under 30 anticipating dialysis initiation within 12 to 24 months, or already on dialysis for less than 1 to 2 years.

Type 1 diabetes with hypoglycemic unawareness or brittle diabetes (PTA indication)

Frequent severe hypoglycemia (blood glucose under 54 with impaired awareness) despite CGM and optimal insulin therapy. Frequent hospitalization for hypoglycemia or DKA. Preserved kidney function. Consideration for pancreas transplant alone or islet cell transplant.

Type 1 diabetes with prior kidney transplant (PAK indication)

Recipient of a kidney transplant (usually living donor) who continues to require insulin and wants to potentially eliminate insulin dependency. The pancreas transplant is added as a second operation.

Rare Type 2 diabetes indication

Occasionally selected Type 2 diabetics with severe insulin dependency and preserved beta cell function may be transplanted. This is rare and controversial.

Total pancreatectomy with islet autotransplantation

Not covered under 5.12. This is a treatment for chronic pancreatitis. Islet autotransplant is different from pancreas allotransplant.

Pre-Transplant Onset Under Multiple Body Systems

Pre-transplant onset for pancreas transplant candidates typically routes through kidney disease or diabetic complications, not through pancreas listings directly (there is no pancreas listing outside of 5.12). Common paths:

Listing 6.03 CKD requiring chronic dialysis

Requires ongoing dialysis (hemodialysis or peritoneal dialysis) expected to last at least 12 months. Most SPK candidates qualified under 6.03 before transplant, sometimes years before.

Listing 6.04 CKD with kidney transplant

1 year auto from kidney transplant date. Relevant for PAK candidates who had a prior kidney transplant.

Listing 6.05 CKD with impairment of kidney function

Two thresholds:

• 6.05A: eGFR of 20 mL/min/1.73 m² or less measured twice at least 90 days apart within a 12 month period
• 6.05B: any of the following complications (2 or more within a 12 month period 60 days apart): renal osteodystrophy with pathologic fractures; peripheral neuropathy; fluid overload requiring hospitalization; anorexia with recent weight loss and BMI under 18

Listing 9.00 endocrine disorders referral

SSA Section 9 does not have specific numeric criteria for diabetes anymore. Diabetes complications are evaluated under the affected body system: retinopathy under 2.03 (visual disorders), neuropathy under 11.14, cardiovascular under Section 4, nephropathy under Section 6, hepatobiliary under Section 5.

Listing 11.14 Peripheral neuropathy

Diabetic peripheral neuropathy causing disorganization of motor function or marked limitation of physical + mental functioning.

Listing 2.02 to 2.04 Visual disorders (diabetic retinopathy)

Proliferative diabetic retinopathy with vision loss meeting Listing 2.02 (impaired visual acuity), 2.03 (contraction of the visual field), or 2.04 (loss of visual efficiency).

Listing 4.02 Chronic heart failure or 4.04 Ischemic heart disease

Type 1 diabetics with 20 to 30 years of disease often have significant coronary artery disease and may qualify under cardiac listings pre-transplant.

What Happens at the 12 Month CDR

Under POMS DI 28010.030, Listing 5.12 is a listing with a specified timeframe and triggers CDR at 12 to 15 months. SSA reviews residual impairment under 5.00G factors. Specific considerations for pancreas transplant:

Pancreas graft function

Best marker of pancreas graft function is insulin independence. Recipients with a functioning graft do not need exogenous insulin and have normal fasting glucose (70 to 100) and HbA1c under 6.0. Pancreatic enzymes (amylase, lipase) may be raised in rejection or graft dysfunction. C-peptide levels rise post-transplant (was low in Type 1 diabetes).

Kidney graft function (for SPK/PAK)

Creatinine trend, eGFR, urinalysis for proteinuria. Best baseline kidney function is at 3 to 6 months post-transplant. Sustained decline warrants biopsy.

Rejection episodes

Acute cellular rejection in pancreas graft occurs in 15 to 30 percent of recipients within year 1. Grading by Banff schema (mild, moderate, severe). PTA has the highest rejection rate. Isolated pancreas biopsy is difficult (graft is intra-abdominal), so rejection is often inferred from raised amylase/lipase, raised fasting glucose, or raised donor-specific antibodies (DSA).

Complications

Graft thrombosis (5 to 10 percent in the first month, higher for PTA), pancreatic leak or fistula, intra-abdominal abscess, CMV disease, PTLD (1 to 3 percent), recurrent autoimmune diabetes (Type 1 recurrence in the graft, 5 to 10 percent), incisional hernia, hypoglycemia from over-functioning graft.

Continuing diabetic complications

Even with a functioning pancreas graft, pre-existing diabetic complications do not reverse. Retinopathy stabilizes but does not typically improve. Nephropathy in native kidneys or transplanted kidney continues. Neuropathy stabilizes. Cardiovascular disease progression slows but does not reverse.

Extending Disability Past 12 Months

Graft failure with return to insulin dependency

If the pancreas graft fails at any point, the recipient returns to insulin dependency. Diabetes complications continue. Evaluate under 6.03 (if kidney also failing), 11.14 (neuropathy), 2.02-2.04 (retinopathy), or 4.02/4.04 (cardiac).

Kidney graft dysfunction (SPK/PAK)

Pancreas and kidney share the same immune response in SPK. Rejection often affects both. If the kidney graft fails, dialysis returns and 6.03 applies.

Ongoing diabetic complications

Retinopathy, neuropathy, cardiovascular disease, and any other pre-transplant complication continues to be evaluated at the CDR.

PTLD

Evaluate under Listing 13.05 (lymphomas) or 13.28. Aggressive treatment supports continued disability.

CNI nephrotoxicity in a PTA recipient

PTA recipients start with preserved kidney function but face 20 to 30 percent CKD progression at 5 years from calcineurin inhibitor use. Evaluate under 6.05.

Pediatric Listing 105.12

Pediatric pancreas transplant is very rare (fewer than 10 per year in the US). Indication is Type 1 diabetes with severe end-organ damage, though pediatric cases are usually treated with intensive insulin therapy or continuous glucose monitoring. Listing 105.12 has identical language: 1 year from transplant date. Pediatric pancreas transplant volume is too small to have dedicated pediatric centers.

Documentation Checklist

1. Pre-transplant medical records: Type 1 diabetes diagnosis with age of onset, C-peptide level, autoantibodies (GAD, IA-2), duration of diabetes
2. Diabetes complications documentation: retinopathy imaging (fluorescein angiography, OCT), neuropathy nerve conduction studies, cardiac stress tests or angiography, nephropathy urine protein and eGFR trends
3. Pre-transplant kidney function trend and dialysis records if applicable (5.03/6.03 documentation)
4. Transplant evaluation notes and UNOS listing date
5. Transplant operative note with exact date and modality (SPK, PAK, or PTA)
6. Transplant discharge summary and early complications (thrombosis, leak, fistula)
7. Post-transplant follow-up notes at 1 month, 3 months, 6 months, and 12 months
8. Insulin independence status (fasting glucose, HbA1c, C-peptide)
9. Pancreatic enzymes (amylase, lipase) if any elevation suggesting rejection
10. Donor-specific antibody testing
11. Kidney graft function for SPK/PAK (creatinine, eGFR, urinalysis)
12. Immunosuppression medication list (tacrolimus, mycophenolate, prednisone; induction with basiliximab, ATG, or alemtuzumab)
13. Antiviral therapy record (valganciclovir for CMV prophylaxis for 3 to 6 months)
14. Complication documentation: CMV/EBV viral loads, imaging for intra-abdominal complications, biopsy findings
15. Treating transplant surgeon or endocrinologist narrative statement or RFC

Four Worked Cases

Case One, Rachel, 47, Minnesota

Rachel has Type 1 diabetes since age 8. Diabetic nephropathy progressed to ESRD by age 44. Started hemodialysis in June 2023. UNOS listed for SPK. Received SPK at University of Minnesota on February 15, 2026. Pre-transplant Rachel qualified under 6.03 (chronic dialysis) starting June 2023. She filed for SSDI in September 2023. Disability onset established at June 15, 2023 (start of dialysis, 6.03A). Retroactive benefits from December 2023 (5 month waiting period). Automatic disability under 5.12 through February 14, 2027. CDR scheduled at 15 months. Rachel achieved insulin independence by day 3 post-transplant and has been insulin-free 6 months later.

Case Two, Michael, 52, Wisconsin

Michael has Type 1 diabetes since age 12. Received a living donor kidney transplant from his sister in March 2024. Continued insulin dependency post-kidney transplant. Underwent PAK at University of Wisconsin on July 20, 2025. Post-op complicated by pancreas graft thrombosis at day 5 requiring graft pancreatectomy. Returned to full insulin dependency. His original kidney transplant 6.04 clock ended March 2025. Now qualifies under 5.12 for 1 year from July 20, 2025 through July 19, 2026 due to the failed pancreas transplant itself. Additional evaluation under 6.05 for CNI nephropathy of the kidney graft, plus diabetic complications, supports continued disability past 12 months.

Case Three, Sarah, 38, North Carolina

Sarah has Type 1 diabetes since age 14 with severe hypoglycemic unawareness. Two ICU admissions for hypoglycemic seizures in 2024. Preserved kidney function (eGFR 78). Underwent PTA at Duke on November 8, 2025. Post-op complicated by A2 rejection at day 45 (treated with steroid pulse and ATG), CMV enteritis at day 90 (treated with IV ganciclovir), and mild kidney dysfunction from tacrolimus (creatinine rose to 1.6, eGFR 45) by month 8. At 12 month CDR (November 2026), pancreas graft functioning (insulin-free, HbA1c 5.9), but CNI-related CKD stage 3 with eGFR 42. Additional evaluation continues under 5.12 residual, and 6.05A may be met at 15 to 18 months if eGFR drops below 20.

Case Four, David, 55, Illinois

David has Type 1 diabetes since age 22, complicated by diabetic retinopathy (proliferative, vitreous hemorrhage twice, meeting 2.03 with visual field contraction 20 degrees), peripheral neuropathy, and ESRD on peritoneal dialysis. Received SPK at Northwestern in April 2025. Insulin independence by day 5. Uncomplicated post-op. At 12 month CDR (April 2026), pancreas and kidney grafts functioning normally, tacrolimus tolerated. However, retinopathy and visual field loss remain unchanged (visual field 20 degrees). Meets Listing 2.03 residual criterion. Disability continues under 2.03 independent of the 5.12 clock.

Denial Counters

Denial reason: 12 months not yet elapsed from transplant date

5.12 does not require 12 months to elapse before filing. The 1 year rule applies from transplant date. File as soon as possible.

Denial reason: DDS wants proof of severity during the 12 month window

5.12 is unconditional. No severity proof required during the 12 month window. Cite 5.00G explicitly. Attach the operative note.

Denial reason: onset date set at transplant date, not pre-transplant

Under 5.00G, onset can be established months or years before transplant based on Type 1 diabetes with end-organ damage. Submit records for kidney disease (6.03 dialysis, 6.05 CKD lab thresholds), retinopathy (2.02-2.04), neuropathy (11.14), or cardiac disease (4.02/4.04).

Denial reason: DDS argues the transplant "cured" the diabetes

The pancreas transplant treats hyperglycemia but does not reverse pre-existing diabetic complications. Retinopathy, established neuropathy, and cardiovascular disease continue at the CDR. Submit records showing these unchanged complications.

Denial reason: CDR terminates at 12 months despite ongoing complications

Appeal within 60 days. Elect to continue benefits during appeal. Submit ongoing complication documentation. Retinopathy (2.02-2.04), neuropathy (11.14), CKD (6.05), cardiac disease (4.02/4.04). Each can independently meet a listing.

State Considerations

Pancreas transplant centers are concentrated at high-volume kidney and multi-organ transplant programs. Highest volume US centers include hospitals in Minnesota (University of Minnesota, historically one of the highest volume pancreas programs in the world), Wisconsin (UW Madison), Pennsylvania (UPMC, Penn), North Carolina (Duke, Wake Forest), Illinois (Northwestern), Washington (University of Washington), California (UCLA, UCSF), Ohio (Ohio State, Cleveland Clinic), and Tennessee (Vanderbilt).

Because pancreas transplant is low volume nationally (about 900 to 1000 per year in the US), regional access varies significantly. UNOS regional pancreas allocation policies affect wait times. Type O and Type A recipients wait longer; Type AB recipients often have shorter waits.

Related Blue Book Reading

• Listing 5.09 Liver Transplantation
• Listing 5.11 Small Intestine Transplantation
• Listings 6.03 / 6.04 / 6.05 Chronic Kidney Disease and Kidney Transplant
• Listing 11.14 Peripheral Neuropathy
• Listing 3.11 Lung Transplantation

Frequently Asked Questions